Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes
Authors
Keywords
-
Journal
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
Volume 327, Issue 6, Pages 534
Publisher
American Medical Association (AMA)
Online
2022-02-09
DOI
10.1001/jama.2022.0078
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial
- (2021) Julio Rosenstock et al. LANCET
- Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial
- (2021) Bernhard Ludvik et al. LANCET
- Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
- (2021) Juan P. Frías et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial
- (2021) Stefano Del Prato et al. LANCET
- Impact of a Weekly Glucagon-Like Peptide 1 Receptor Agonist, Albiglutide, on Glycemic Control and on Reducing Prandial Insulin Use in Type 2 Diabetes Inadequately Controlled on Multiple Insulin Therapy: A Randomized Trial
- (2020) Julio Rosenstock et al. DIABETES CARE
- Efficacy and Safety of Short- and Long-Acting Glucagon-Like Peptide 1 Receptor Agonists on a Background of Basal Insulin in Type 2 Diabetes: A Meta-analysis
- (2020) Jessica A. Huthmacher et al. DIABETES CARE
- Glucagon-like peptide-1 receptor co-agonists for treating metabolic disease
- (2020) Laurie L. Baggio et al. Molecular Metabolism
- Separate and Combined Gluco-Metabolic Effects of Endogenous Glucose-Dependent Insulinotropic Polypeptide and Glucagon-Like Peptide-1 in Healthy Individuals
- (2019) Lærke S. Gasbjerg et al. DIABETES
- Efficacy, Safety, and Tolerability of Oral Semaglutide Versus Placebo Added to Insulin With or Without Metformin in Patients With Type 2 Diabetes: The PIONEER 8 Trial
- (2019) Bernard Zinman et al. DIABETES CARE
- Unknown
- (2018) DIABETES OBESITY & METABOLISM
- Semaglutide Added to Basal Insulin in Type 2 Diabetes (SUSTAIN 5): A Randomized, Controlled Trial
- (2018) Helena W Rodbard et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial
- (2018) Juan Pablo Frias et al. LANCET
- Pharmacology, Physiology, and Mechanisms of Incretin Hormone Action
- (2013) Jonathan E. Campbell et al. Cell Metabolism
- Insulin Therapy for Type 2 Diabetes
- (2009) S. G. Swinnen et al. DIABETES CARE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More